140 related articles for article (PubMed ID: 37796409)
1. Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective.
Coughlan D; Arisa O; Thomson K; Yu G; Pearson F; Kernohan A; Gonzalez-Moral SG; Wallace S; Rice S
Pharmacoeconomics; 2024 Jan; 42(1):5-9. PubMed ID: 37796409
[No Abstract] [Full Text] [Related]
2. Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit?
Mosele F; Di Maio M
Ann Oncol; 2023 Jul; 34(7):567-568. PubMed ID: 37349024
[No Abstract] [Full Text] [Related]
3. Trastuzumab deruxtecan beats trastuzumab emtansine in lowered disease progression, death.
Cancer; 2022 Aug; 128(15):2852. PubMed ID: 35797061
[No Abstract] [Full Text] [Related]
4. Trastuzumab Deruxtecan Is Effective in HER2-Low Breast Cancer.
Cancer Discov; 2020 Apr; 10(4):488. PubMed ID: 32111601
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
Tarantino P; Tolaney SM; Curigliano G
Ann Oncol; 2023 Oct; 34(10):949-950. PubMed ID: 37499870
[No Abstract] [Full Text] [Related]
6. The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
Wei T; Wang D; Yuan P
Ann Oncol; 2023 Oct; 34(10):948-949. PubMed ID: 37499869
[No Abstract] [Full Text] [Related]
7. [Ⅱ. Application for HER2-Positive Breast Cancer(Trastuzumab Deruxtecan)].
Naito Y
Gan To Kagaku Ryoho; 2021 Dec; 48(12):1452-1453. PubMed ID: 34911910
[No Abstract] [Full Text] [Related]
8. Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients.
Seban RD; Champion L; Bellesoeur A; Vincent-Salomon A; Bidard FC
J Nucl Med; 2023 Jul; 64(7):1164-1165. PubMed ID: 37230529
[No Abstract] [Full Text] [Related]
9. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
[TBL] [Abstract][Full Text] [Related]
11. In brief: Fam-trastuzumab deruxtecan (Enhertu) for breast cancer.
Med Lett Drugs Ther; 2023 Apr; 65(1673):e60-e61. PubMed ID: 37020344
[No Abstract] [Full Text] [Related]
12. Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer.
O'Rourke K
Cancer; 2022 Mar; 128(5):938. PubMed ID: 35147987
[No Abstract] [Full Text] [Related]
13. [New drugs approval: Trastuzumab-deruxtecan - HER2-low metastatic breast cancer].
Gorgeu V; Grellety T
Bull Cancer; 2023 Jun; 110(6):597-598. PubMed ID: 37045733
[No Abstract] [Full Text] [Related]
14. Breaking Barriers in HER2+ Cancers.
Siena S; Marsoni S; Sartore-Bianchi A
Cancer Cell; 2020 Sep; 38(3):317-319. PubMed ID: 32857948
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
16. Two drugs for advanced HER2-positive breast cancer (Enhertu and Tukysa).
Med Lett Drugs Ther; 2020 Nov; 62(1611):182-184. PubMed ID: 33429416
[No Abstract] [Full Text] [Related]
17. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I;
N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S; Jacot W; Yamashita T; Sohn J; Vidal M; Tokunaga E; Tsurutani J; Ueno NT; Prat A; Chae YS; Lee KS; Niikura N; Park YH; Xu B; Wang X; Gil-Gil M; Li W; Pierga JY; Im SA; Moore HCF; Rugo HS; Yerushalmi R; Zagouri F; Gombos A; Kim SB; Liu Q; Luo T; Saura C; Schmid P; Sun T; Gambhire D; Yung L; Wang Y; Singh J; Vitazka P; Meinhardt G; Harbeck N; Cameron DA;
N Engl J Med; 2022 Jul; 387(1):9-20. PubMed ID: 35665782
[TBL] [Abstract][Full Text] [Related]
19. [New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2].
Minot-This MS; Bellesoeur A
Bull Cancer; 2021 Sep; 108(9):783-784. PubMed ID: 34144792
[No Abstract] [Full Text] [Related]
20. [Ⅲ. Clinical Trials of Trastuzumab Deruxtecan for HER2-Low Advanced Breast Cancer].
Kizawa R; Takano T
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1278-1281. PubMed ID: 38247065
[No Abstract] [Full Text] [Related]
[Next] [New Search]
